摘要:
An implantable medical device includes a lead configured to be located proximate to the left ventricle (LV) of the heart, the lead including multiple LV electrodes to sense cardiac activity at multiple LV sensing sites. The a detection module to detect an arrhythmia that represents at least one of a tachycardia and fibrillation based at least in part on the cardiac activity sensed at the multiple LV sensing sites. The ATP therapy module to identify at least one of an ATP configuration or an ATP therapy site based on the cardiac sensed activity at the LV sensing sites, the ATP therapy module to control delivery of antitachycardia pacing (ATP) therapy at the ATP therapy site. The ATP therapy module delivers a stimulus to electrodes at one or more of an LV site, right ventricular (RV) site and right atrial (RA) site, the detection module to sense evoked responses at the LV sensing sites, the ATP therapy module to designate the ATP therapy site to include at least the LV sensing site with a shortest activation time relative to the one or more LV site, RV site and RA site where the stimulus is delivered.
摘要:
Techniques are provided for use with an implantable cardiac stimulation device equipped for multi-site left ventricular (MSLV) pacing using a multi-pole LV lead. In one example, referred to herein as QuickStim, cardiac pacing configurations are optimized based on an assessment of hemodynamic benefit and device longevity. In another example, referred to herein as QuickSense, cardiac sensing configurations are optimized based on sensing profiles input by a clinician. Various virtual sensing channels are also described that provide for the multiplexing or gating of sensed signals. Anisotropic oversampling is also described.
摘要:
Techniques are provided for use with an implantable cardiac stimulation device equipped for multi-site left ventricular (MSLV) pacing using a multi-pole LV lead. In one example, referred to herein as QuickStim, cardiac pacing configurations are optimized based on an assessment of hemodynamic benefit and device longevity. In another example, referred to herein as QuickSense, cardiac sensing configurations are optimized based on sensing profiles input by a clinician. Various virtual sensing channels are also described that provide for the multiplexing or gating of sensed signals. Anisotropic oversampling is also described.
摘要:
Techniques are provided for use with an implantable cardiac stimulation device equipped for multi-site left ventricular (MSLV) pacing using a multi-pole LV lead. In one example, referred to herein as QuickStim, cardiac pacing configurations are optimized based on an assessment of hemodynamic benefit and device longevity. In another example, referred to herein as QuickSense, cardiac sensing configurations are optimized based on sensing profiles input by a clinician. Various virtual sensing channels are also described that provide for the multiplexing or gating of sensed signals. Anisotropic oversampling is also described.
摘要:
Techniques are provided for use with an implantable cardiac stimulation device equipped for multi-site left ventricular (MSLV) pacing using a multi-pole LV lead. In one example, referred to herein as QuickStim, cardiac pacing configurations are optimized based on an assessment of hemodynamic benefit and device longevity. In another example, referred to herein as QuickSense, cardiac sensing configurations are optimized based on sensing profiles input by a clinician. Various virtual sensing channels are also described that provide for the multiplexing or gating of sensed signals. Anisotropic oversampling is also described.
摘要:
Specific embodiments of the present invention use an implanted sensor, during a period of time, to measure a physiologic property when the patient's heart is not stressed, and when the patient's heart is stressed. A slope is determined, where the slope is indicative of a change in the physiologic property during the period of time. Heart disease is monitored based on a magnitude of the slope. In further embodiments of the present invention, a slope indicative of a change in a physiologic property during a period of time is determined, for each of a plurality of periods of time. Changes in the patient's heart disease are monitored based on changes in the slope.
摘要:
Implantable systems and method for use therewith are provided that take advantage of various neuromodulation and neurosensing techniques for either preventing atrial fibrillation (AF) or terminating AF. Specific embodiments are for use with an implantable device that includes one or more atrial electrode for sensing atrial fibrillation (AF) and/or delivering Atrial Anti-Tachycardia Pacing (AATP) and one or more electrode for monitoring and/or stimulating atrial vagal fat pads.
摘要:
Provided herein are implantable systems, and methods for use therewith, that increase the accuracy of measurements produced using an implanted sensor, where the measurements are affected by cycles of a cyclical body function (e.g., heart beat and/or respiration). In accordance with specific embodiments of system, a measurement that is presumed to be accurate is obtained. The measurement can be of a physiologic property, such as, but not limited to, blood oxygen saturation, hematocrit, or blood glucose concentration. Additionally, the implanted is used to produce a plurality of measurements of the physiologic property. Such measurements, produced using the implanted sensor, are compared to the measurement presumed to be accurate to thereby identify when the measurements produced using the implanted sensor are most accurate. Thereafter, the implanted system is configured to use the implanted sensor to produce measurements when the measurements produced using the implanted sensor are most accurate.
摘要:
Methods for assessing, diagnosing and treating medical conditions using SvO2 and hematocrit measurements alone, or in combination with other measurements related to cardiac activity are provided. These includes methods for distinguishing true anemia from diluted anemia, methods for anemia detection, methods for measuring disease progression based on anemia trending, methods for managing therapy delivery, methods for managing heart failure drug therapies, methods for cardiac output optimization based on SvO2, methods for cardiac resynchronization therapy lead placement, method for detection of heart failure decompensation, and methods to monitor and treat systolic versus diastolic heart failure are provided.
摘要:
Implantable systems, and method for use therewith, are provided that take advantage of various neuromodulation and neurosensing techniques for either preventing atrial fibrillation (AF) or terminating AF. Specific embodiments, as will be described below, are for use with an implantable device that include one or more atrial electrode for sensing atrial fibrillation (AF) and/or delivering AATP and one or more electrode for monitoring and/or stimulating atrial vagal fat pads.